Analysts at Canaccord Genuity began coverage on shares of VBI Vaccines, Inc. (NASDAQ:VBIV) in a research note issued on Wednesday. The brokerage set a “buy” rating and a $10.00 price target on the biopharmaceutical company’s stock. Canaccord Genuity’s price target would indicate a potential upside of 162.47% from the stock’s previous close.
A number of other research firms have also recently issued reports on VBIV. ValuEngine cut shares of VBI Vaccines from a “hold” rating to a “sell” rating in a research note on Thursday, August 3rd. Noble Financial restated a “buy” rating on shares of VBI Vaccines in a research note on Monday, July 31st. Finally, Zacks Investment Research upgraded shares of VBI Vaccines from a “sell” rating to a “hold” rating in a research note on Wednesday, August 30th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $10.00.
TRADEMARK VIOLATION WARNING: “VBI Vaccines, Inc. (VBIV) Coverage Initiated at Canaccord Genuity” was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2017/11/03/vbi-vaccines-inc-vbiv-coverage-initiated-at-canaccord-genuity.html.
In related news, major shareholder Opko Health, Inc. bought 655,738 shares of the business’s stock in a transaction dated Monday, October 30th. The stock was bought at an average price of $3.05 per share, for a total transaction of $2,000,000.90. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Steven Gillis bought 300,000 shares of the business’s stock in a transaction dated Monday, October 30th. The shares were bought at an average price of $3.05 per share, with a total value of $915,000.00. Following the purchase, the director now owns 46,916 shares in the company, valued at approximately $143,093.80. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 4,078,738 shares of company stock valued at $12,444,511. 54.50% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently modified their holdings of VBIV. Northern Trust Corp acquired a new stake in VBI Vaccines in the 2nd quarter worth about $883,000. State Street Corp acquired a new stake in VBI Vaccines in the 2nd quarter worth about $831,000. KCG Holdings Inc. acquired a new stake in VBI Vaccines in the 1st quarter worth about $512,000. Goldman Sachs Group Inc. acquired a new stake in VBI Vaccines in the 1st quarter worth about $383,000. Finally, TIAA CREF Investment Management LLC acquired a new stake in VBI Vaccines in the 2nd quarter worth about $262,000. Institutional investors and hedge funds own 31.50% of the company’s stock.
About VBI Vaccines
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
What are top analysts saying about VBI Vaccines Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for VBI Vaccines Inc. and related companies.